EIKNEikon Therapeutics, Inc.
$7.48
$7.48
$7.3152 weeks$16.26
Price
End-of-day closes, not the intraday tick.
The five questions
1 of 5 availableOnly one of the five can be answered for EIKN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?not enough filed
P/En/a
Market value$405.0M
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
Eikon Therapeutics, Inc. (EIKN) reported revenue of $5.0M in Q2 2026 (quarter ended Jun 30, 2026), up 59% from the same quarter a year earlier. That came with net loss of $88M. The next results filing is expected around Nov 12, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 14, 2026EIK1001 – TLR7/8 Dual-Agonist.Regulation FD disclosure · press release
- Aug 13, 2026Eikon Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Aug 3, 2026Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the “Company”). Dr. Chen’s and Mr. Wolfe’s resignations were not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry